CD14+CD16+ monocytes are involved in daratumumab‐mediated myeloma cells killing and in anti‐CD47 therapeutic strategy
- 12 March 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 190 (3), 430-436
- https://doi.org/10.1111/bjh.16548
Abstract
A deep elucidation of the mechanisms of action of anti‐CD38 monoclonal antibodies (mAbs), such as daratumumab (DARA), is required to identify patients with multiple myeloma (MM) who are more responsive to this treatment. In the present study, an autologous ex vivo approach was established, focussing on the role of the monocytes in the anti CD38‐mediated killing of MM cells. In bone marrow (BM) samples from 29 patients with MM, we found that the ratio between monocytes (CD14+) and MM cells (CD138+) influences the response to DARA. Further, the exposure of the BM samples to DARA is followed by the formation of a CD138+CD14+ double‐positive (DP) population, that quantitatively correlates with the anti‐MM cells killing. These effects were dependent on the presence of a CD14+CD16+ monocyte subset and on high CD16 expression levels. Lastly, the addition of a mAb neutralising the CD47/signal‐regulatory protein α (SIRPα) axis was able to increase the killing mediated by DARA. The effects were observed only in coincidence with high CD14+:CD138+ ratio, with a significant presence of the DP population and were correlated with CD16 expression. In conclusion, the present study underlines the critical role of the CD16+ monocytes in DARA anti‐MM killing effects and gives a rationale to test the combination of an anti‐CD47 mAb with anti‐CD38 mAbs.Funding Information
- International Myeloma Foundation
- Associazione Italiana per la Ricerca sul Cancro (20299)
This publication has 15 references indexed in Scilit:
- Programmable bacteria induce durable tumor regression and systemic antitumor immunityNature Medicine, 2019
- Daratumumab induces CD38 internalization and impairs myeloma cell adhesionOncoImmunology, 2018
- Immunomodulatory effects of CD38-targeting antibodiesImmunology Letters, 2018
- Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaBritish Journal of Haematology, 2018
- CD38 antibodies in multiple myeloma: back to the futureBlood, 2018
- CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumabOncoImmunology, 2018
- Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabClinical Cancer Research, 2017
- IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclastsHaematologica, 2017
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma ModelCells, 2015
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cellsLeukemia, 2012